Hong Sang

Array ( [id] => 16726583 [patent_doc_number] => 20210093730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => BIOMARKERS FOR ANTIBODY-DRUG CONJUGATE MONOTHERAPY OR COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 17/038868 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31057 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17038868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19608909 [patent_doc_number] => 12157775 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-03 [patent_title] => Methods of using bispecific antigen-binding constructs targeting HER2 [patent_app_type] => utility [patent_app_number] => 17/033441 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 84 [patent_figures_cnt] => 130 [patent_no_of_words] => 53313 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 335 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17033441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18970470 [patent_doc_number] => 20240050562 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => INHIBITOR OF CELL PROLIFERATION IN OBINUTUZUMAB RESISTANT CD20-POSITIVE CANCER, AND MEDICINAL COMPOSITION, MEDICINE, PRODUCTION, METHOD FOR INHIBITING CELL PROLIFERATION, THERAPEUTIC METHOD, TYPE II ANTI-CD20 ANTIBODY, COMPOUNDS, COMBINATION OF SAME, ENHANCER AND INDUCER, EACH RELATING THERETO [patent_app_type] => utility [patent_app_number] => 17/766280 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17756273 [patent_doc_number] => 11396557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-26 [patent_title] => Bispecific antibody or antibody mixture with common light chains [patent_app_type] => utility [patent_app_number] => 17/022545 [patent_app_country] => US [patent_app_date] => 2020-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 28 [patent_no_of_words] => 18281 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 296 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17022545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19210744 [patent_doc_number] => 11999792 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Antibody therapeutics that bind CD38 [patent_app_type] => utility [patent_app_number] => 17/016104 [patent_app_country] => US [patent_app_date] => 2020-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 23050 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17016104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628786 [patent_doc_number] => 20210047439 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => DLL3 BINDING PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/999773 [patent_app_country] => US [patent_app_date] => 2020-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47104 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16999773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18779119 [patent_doc_number] => 11820813 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-21 [patent_title] => Anti-neurotensin long fragment antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/994770 [patent_app_country] => US [patent_app_date] => 2020-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 13 [patent_no_of_words] => 16141 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16994770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20256148 [patent_doc_number] => 12428491 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => PSMA and CD3 bispecific T cell engaging antibody constructs [patent_app_type] => utility [patent_app_number] => 16/994953 [patent_app_country] => US [patent_app_date] => 2020-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 18 [patent_no_of_words] => 48773 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16994953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20256148 [patent_doc_number] => 12428491 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => PSMA and CD3 bispecific T cell engaging antibody constructs [patent_app_type] => utility [patent_app_number] => 16/994953 [patent_app_country] => US [patent_app_date] => 2020-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 18 [patent_no_of_words] => 48773 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16994953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18666303 [patent_doc_number] => 11773181 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Anti-survivin antibodies for cancer therapy [patent_app_type] => utility [patent_app_number] => 16/990622 [patent_app_country] => US [patent_app_date] => 2020-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 10255 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 198 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16990622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657457 [patent_doc_number] => 20210054093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => Novel CD47 Monoclonal Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/989702 [patent_app_country] => US [patent_app_date] => 2020-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14930 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 352 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18887725 [patent_doc_number] => 11866487 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Filamin A binding proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 16/935596 [patent_app_country] => US [patent_app_date] => 2020-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 39450 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 382 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16935596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16613674 [patent_doc_number] => 20210032327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/934143 [patent_app_country] => US [patent_app_date] => 2020-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16934143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17053598 [patent_doc_number] => 20210263032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => LIQUID BIOPSY YIELD ENHANCEMENT [patent_app_type] => utility [patent_app_number] => 16/932989 [patent_app_country] => US [patent_app_date] => 2020-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16932989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398844 [patent_doc_number] => 20200339702 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => DE-IMMUNISED ANTI-ERBB3 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/925570 [patent_app_country] => US [patent_app_date] => 2020-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24556 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16925570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18871201 [patent_doc_number] => 11858988 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-02 [patent_title] => Antibodies specific for claudin 6 (CLDN6) [patent_app_type] => utility [patent_app_number] => 16/922179 [patent_app_country] => US [patent_app_date] => 2020-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 31 [patent_no_of_words] => 40119 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 567 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16922179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590560 [patent_doc_number] => 10899810 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => B*44 restricted peptides for use in immunotherapy against cancers and related methods [patent_app_type] => utility [patent_app_number] => 16/916447 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 41 [patent_no_of_words] => 41939 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16916447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590561 [patent_doc_number] => 10899811 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => B*44 restricted peptides for use in immunotherapy against cancers and related methods [patent_app_type] => utility [patent_app_number] => 16/916450 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 41 [patent_no_of_words] => 42203 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16916450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16696732 [patent_doc_number] => 10947313 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Anti-EphA4 antibody [patent_app_type] => utility [patent_app_number] => 16/915412 [patent_app_country] => US [patent_app_date] => 2020-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 24 [patent_no_of_words] => 19353 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16915412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16375125 [patent_doc_number] => 20200323967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/915283 [patent_app_country] => US [patent_app_date] => 2020-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33187 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16915283 [rel_patent_id] =>[rel_patent_doc_number] =>)